The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma
BackgroundBispecific antibodies (BsAbs) are widely used for the treatment of multiple myeloma (MM), but their long-term safety still provokes concerns.MethodsAdverse event (AE) data on teclistamab, talquetamab, and elranatamab between 1 August 2022 and 30 September 2024 were retrieved from the Food...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1593405/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|